Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aphria Inc. stock logo
APHA
Aphria
$15.38
$15.48
$2.78
$32.29
$4.87B2.6721.83 million shsN/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$6.31
-2.6%
$5.60
$3.96
$9.85
$2.34B0.412.54 million shs902,877 shs
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$14.74
$14.62
$6.38
$14.76
$1.87B0.193.08 million shs3.45 million shs
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
C$0.00
C$14.01
C$36.02
C$10.76BN/A1.38 million shs1.23 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aphria Inc. stock logo
APHA
Aphria
0.00%0.00%0.00%0.00%0.00%
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-2.70%-1.87%+1.89%+23.12%-17.19%
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00%0.00%0.00%0.00%0.00%
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aphria Inc. stock logo
APHA
Aphria
N/AN/AN/AN/AN/AN/AN/AN/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
3.4859 of 5 stars
1.94.00.04.00.63.30.6
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/AN/AN/AN/A
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aphria Inc. stock logo
APHA
Aphria
0.00
N/AN/AN/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
1.83
Reduce$7.3015.69% Upside
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00
N/AN/AN/A
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest APHA, VRX, BHC, and BLU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aphria Inc. stock logo
APHA
Aphria
$405.96M12.00$0.09 per share166.43$4.80 per share3.20
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$9.73B0.24$7.51 per share0.84($0.89) per share-7.09
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$15K124,613.93N/AN/A$3.09 per share4.77
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aphria Inc. stock logo
APHA
Aphria
-$63.21M-$0.06N/A219.71N/A-36.10%-2.30%-1.66%N/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-$46M-$0.11N/A1.35N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)
BELLUS Health Inc. stock logo
BLU
BELLUS Health
-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/A
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest APHA, VRX, BHC, and BLU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$0.9320N/AN/AN/A$2.47 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aphria Inc. stock logo
APHA
Aphria
N/AN/AN/AN/AN/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/AN/AN/AN/AN/A
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/A
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aphria Inc. stock logo
APHA
Aphria
0.25
2.36
1.17
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/A
1.35
0.97
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/A
33.42
33.42
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aphria Inc. stock logo
APHA
Aphria
10.30%
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
78.65%
BELLUS Health Inc. stock logo
BLU
BELLUS Health
90.37%
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
N/A

Insider Ownership

CompanyInsider Ownership
Aphria Inc. stock logo
APHA
Aphria
N/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
8.05%
BELLUS Health Inc. stock logo
BLU
BELLUS Health
24.17%
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Aphria Inc. stock logo
APHA
Aphria
1,200316.80 millionN/AOptionable
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20,700370.08 million340.29 millionOptionable
BELLUS Health Inc. stock logo
BLU
BELLUS Health
74126.81 million96.16 millionNot Optionable
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
N/A349.30 millionN/ANot Optionable

Recent News About These Companies

Valeant Pharma acquires Medicis for US $2.6 billion
SCOTUS Passes on Valeant's Challenge to False Claims Act Ruling
Kiniksa Pharmaceuticals International PLC Class A
Valeant Urges SCOTUS to Clarify Disclosure Rule in Fraud Law
Valeant Pharmaceuticals International, Inc. (VRX.TO)
Love Him or Hate Him, Ackman Now Runs the Worlds Top Hedge Fund
Branded Generics Global Market Report 2023
Despite Woes, Valeant May Be Headed for a Rebound
Valeant Pharmaceuticals International, Inc. (VRX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aphria stock logo

Aphria NASDAQ:APHA

Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.

Bausch Health Cos stock logo

Bausch Health Cos NYSE:BHC

$6.31 -0.17 (-2.62%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$6.42 +0.11 (+1.81%)
As of 07/18/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

BELLUS Health stock logo

BELLUS Health NASDAQ:BLU

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Valeant Pharmaceuticals International stock logo

Valeant Pharmaceuticals International TSE:VRX

Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.